Lilly unveils mirikizumab data in ulcerative colitis as it preps filings

Eli Lilly has reported phase 3 results with its ulcerative colitis challenger mirikizumab, as it waits for the readout of a second trial in the coming weeks that will allow it to file for regulatory approvals.